NMNadia Samy Mahmoud

Nadia Samy Mahmoud

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nadia Samy Mahmoud has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nanomaterial-Assisted Stem Cell-Based Therapy for Primary Osteoporosis: Challenges and Future Trends

    by Nadia S Mahmoud, Hanaa H Ahmed, Mohamed R Mohamed, Mohamed A M Ali, Hadeer A Aglan

    Osteoporosis is a global health crisis affecting millions of people worldwide, and its incidence increases as a consequence of the increase in the percentage of aged people within the population. Osteoporosis-related fractures are the most prominent reasons for disability and mortality. Bone is continually remodeled to sustain its structural integrity and mineral content. Any imbalance in bone remodeling activity could lead to many bone disorders. Current therapeutic interventions in osteoporosis target resorptive and anabolic events. Although these treatment modalities aim to reduce the intensity of bone remodeling, they fail to reverse the structural damage. PubMed, Google Scholar, and ScienceDirect were searched for all relevant English-language publications. This review synthesizes findings from 135 studies published between 2000 and 2025 that investigate nanomaterial-based differentiation of mesenchymal stem cells (MSCs). MSCs have been recognized as an excellent cell source for regenerative medicine due to their remarkable characteristics. Accumulating evidence suggests that integrating stem cells with nanomaterials opens a new avenue for tissue repair and regeneration and could significantly influence stem cell fate. Integrating stem cells with nanomaterials introduces a paradigm shift from passive cell carriers to bio-instructive systems, in which the nanostructure directly activates osteogenic signaling pathways, leading to enhanced osteogenesis independent of osteogenic factors. Moreover, it discusses the therapeutic potential of osteoblast transplantation in both preclinical and clinical trials for managing bone defects, including osteoporosis. Osteoblast therapy could offer new insights into the future direction of osteoporosis therapy owing to its specificity and minimal side effects compared to current medication. Despite the promising outcomes in pre-clinical settings, further studies are required to establish the optimal safe dosage and to elucidate the underlying mechanism of action. If proven effective, osteoblast transplantation could be eligible for clinical translation.

  • Open Access

    Geltrex-based protocol for the differentiation of rat adipose tissue–derived mesenchymal stem cells into insulin-producing cells: in vitro and in vivo considerations

    by Hanaa H. Ahmed, Nadia S. Mahmoud, Hadeer A. Aglan

    Diabetes mellitus (DM) is a chronic illness manifested by uncontrolled glycemic levels. The present investigation was designed to explore the role of Geltrex, integrated with inducing factors, in driving the differentiation of rat adipose tissue–extracted mesenchymal stem cells (ADSCs) into efficient insulin-producing cells (IPCs) and to appraise the curative effect of the generated IPCs against type I DM rat model elicited by intraperitoneal injection of streptozotocin. ADSCs were harvested, characterized, and stimulated to differentiate into IPCs using a Geltrex matrix supplemented by a mixture of growth factors and other differentiation-inducing factors. The identity of the resultant IPCs was affirmed by measuring the expression levels of IPC-related genes and an insulin secretion assay. Then, the therapeutic efficacy of the well-characterized IPCs was assessed via implantation in a diabetic rat model. The Geltrex-based differentiation protocol successfully generated functional IPCs displaying upregulated levels of pancreatic endocrine genes. Moreover, the PKH-26 staining monitored the engraftment of IPCs into the pancreas of the treated rats. Additionally, IPC transplantation in diabetic rats elicited a significant enhancement in metabolic indices and motivated a significant overexpression of the pancreatic-specific genes. The therapeutic impact of the inoculated IPCs was further evidenced by the remarkable improvement in the histological architecture of the pancreatic tissue of the treated rats. The Geltrex-dependent differentiation protocol could be an optimum one for producing functional IPCs, derived from rat ADSCs, which could be an essential precept for future clinical application in the treatment of DM. Graphical Abstract


  • Open Access

    The efficacy of bone marrow-derived mesenchymal stem cells in restoring limbal stem cell deficiency in rat model

    by Mohamed A. El-Desouky, Nadia Samy Mahmoud, Fayek M. Ghaleb, Fatma B. Rashidi, Iman M. A. Zaki, Marwa A. Fouly, Ahmed M. Ata, Hanaa Hamdy Ahmed

    This approach aimed to assess the therapeutic significance of BM-MSCs in alleviating LSCD elicited in rats via corneal alkali burns and to explore the associated repairing mechanisms. Rats were assigned to (1) control group, (2) alkali burn group, and (3) stem cells group. Corneal surface investigations were performed using a slit lamp and fluorescence tests. The therapeutic impact of BM-MSCs was appraised by estimating the protein levels of TNF-α, SOD, VEGF, MMP-2, and IL-8 using ELISA. Moreover, mRNA transcription levels of corneal TNF-α, NF-kB, COX-2, and caspase-3 were quantified. Histological investigation and immunostaining of corneal cytokeratin 3 and p63 proteins were also conducted. The results indicated that BM-MSCs treatment enhanced the corneal wound healing, decreased corneal opacity, and neovascularization. Moreover, such treatment resulted in a significant decline in corneal TNF-α, IL-8, VEGF, and MMP-2 protein levels. Additionally, stem cells group elicited a significant down-expression of TNF-α, NF-κB, COX-2, and caspase-3 genes. Besides, BM-MSCs treatment restored the corneal epithelial integrity and ameliorated the pathological characteristics, as confirmed by histological and immunohistochemical analysis. Conclusively, the present investigation underscores the healing ability of BM-MSCs in LSCD in the rat model by repairing the damaged corneal epithelium through withstanding inflammation, angiogenesis, and apoptosis. Consequently, MSCs transplantation represents a promising therapeutic modality for LSCD.


  • Open Access

    Role of CD133 antibody-conjugated nanocarrier in enhancing the targetability of hepatocellular carcinoma stem cells

    by Hadeer A. Aglan, Ahmed A. Abd-Rabou, Hanaa H. Ahmed, Ghada H. Elsayed, Mohamed S. Kishta, Manar A. Elhinnawi, Nadia S. Mahmoud

    This study aimed at targeting hepatic cancer stem cells (CSCs) with quercetin (Q) or kaempferol (K) loaded into poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs) decorated with CD133 antibody. For this purpose, the formulated Q NPs and K NPs and their free forms were evaluated for their cytotoxic potential, apoptotic activity, and anti-migratory effect against CD133+ CSCs isolated from the Huh7 cell line. Moreover, their influence on the hepatic CSCs-relevant molecular pathways was evaluated through analyzing several related gene expression levels. Interestingly, the in vitro study revealed that the Q NPs and K NPs and their free forms exhibit significant cytotoxic potential against CSCs isolated from the Huh7 cell line. The flow cytometric analysis revealed that Q NPs recorded the highest induction of apoptosis (77.8%) relative to the control (1.8%). The migration of hepatic CSCs is restrained by treatment with the suggested NPs and their free forms, but the most pronounced effect was observed after treatment with Q NPs. Both Q NPs and K NPs triggered significant down-regulation in the expression level of ABCG2, survivin, vimentin, cyclin D1, c-Myc, MMP-7, and VEGF genes in hepatic CSCs. The treatment with Q NPs motivated significant up-regulation in the expression level of the P53 gene in hepatic CSCs. Conclusively, the obtained results shed light on the success of Q NPs and K NPs modified with CD133 antibody on their surfaces in targeting hepatic CSCs. This effect was evidenced by their ability to significantly induce apoptosis, inhibit metastasis, reverse drug resistance, and interfere with CSC-associated signaling pathways.


  • Open Access

    Acquisition of durable insulin-producing cells from human adipose tissue-derived mesenchymal stem cells as a foundation for cell- based therapy of diabetes mellitus

    by Ghada Nour Eldeen, Hadeer A. Aglan, Nadia S. Mahmoud, Mazen Abdel Rasheed, Osama M. Azmy, Hanaa H. Ahmed

    This study aimed to identify the suitable induction protocol to produce highly qualified insulin producing cells (IPCs) from human adipose tissue derived stem cells (ADSCs) and evaluate the efficacy of the most functionally IPCs in management of diabetes mellitus (DM) in rats. The ADSCs were isolated and characterized according to the standard guidelines. ADSCs were further induced to be IPCs in vitro using three different protocols. The success of trans-differentiation was assessed in vitro through analysis of pancreatic endocrine genes expression, and insulin release in response to glucose stimulation. Then, the functionalization of the generated IPCs was evaluated in vivo. The in vitro findings revealed that the laminin-coated plates in combination with insulin-transferrin-selenium, B27, N2, and nicotinamide could efficiently up-regulate the expression of pancreatic endocrine genes. The in vivo study indicated effectual homing of the PKH-26-labelled IPCs in the pancreas of treated animals. Moreover, IPCs infusion in diabetic rats induced significant improvement in the metabolic parameters and prompted considerable up-regulation in the expression of the pancreatic related genes. The regenerative effect of infused IPCs was determined through histological examination of pancreatic tissue. Conclusively, the utilization of laminin–coated plates in concomitant with extrinsic factors promoting proliferation and differentiation of ADSCs could efficiently generate functional IPCs.


  • Open Access

    The Promising Role of hypoxia-resistant insulin-producing Cells in Ameliorating Diabetes Mellitus In Vivo

    by Hanaa H Ahmed, Hadeer A Aglan, Hanan H Beherei, Mostafa Mabrouk, Nadia S Mahmoud

    Aim: This study aimed to evaluate the efficacy of hypoxia-persistent insulin-producing cells (IPCs) against diabetes in vivo. Materials & methods: Mesenchymal stem cells (MSCs) differentiation into... Plain language summary Transplantation of cells that can release insulin have been reported as an alternate method to islet transfer for curing diabetes; however, the main difficulty facing the qua... Graphical abstract


  • Nanomaterial-induced mesenchymal stem cell differentiation into osteoblast for counteracting bone resorption in the osteoporotic rats

    by Nadia S. Mahmoud, Mohamed R. Mohamed, Mohamed A.M. Ali, Hadeer A. Aglan, Khalda S. Amr, Hanaa H. Ahmed


  • Osteoblast-Based Therapy—A New Approach for Bone Repair in Osteoporosis: Pre-Clinical Setting

    by Nadia Samy Mahmoud, Mohamed Ragaa Mohamed, Mohamed Ahmed Mohamed Ali, Hadeer Ahmed Aglan, Khalda Sayed Amr, Hanaa Hamdy Ahmed

    Background: Osteoporosis is a metabolic bone disease characterized by low bone density resulting in increased fracture susceptibility. This research was constructed to uncover the potential therapeutic application of osteoblasts transplantation, generated upon culturing male rat bone marrow-derived mesenchymal stem cells (BM-MSCs) in osteogenic medium (OM), OM containing gold (Au-NPs) or gold/hydroxyapatite (Au/HA-NPs) nanoparticles, in ovariectomized rats to counteract osteoporosis. Methods: Forty rats were randomized into: (1) negative control, (2) osteoporotic rats, whereas groups (3), (4) and (5) constituted osteoporotic rats treated with osteoblasts yielded from culturing BM-MSCs in OM, OM plus Au-NPs or Au/HA-NPs, respectively. After 3 months, osterix (OSX), bone alkaline phosphatase (BALP), sclerostin (SOST) and bone sialoprotein (BSP) serum levels were assessed. In addition, gene expression levels of cathepsin K, receptor activator of nuclear factor-Îşb ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio were evaluated using real-time PCR. Moreover, histological investigation of femur bone tissues in different groups was performed. The homing of implanted osteoblasts to the osteoporotic femur bone of rats was documented by Sex determining region Y gene detection in bone tissue. Results: Our results indicated that osteoblasts infusion significantly blunted serum BALP, BSP and SOST levels, while significantly elevated OSX level. Also, they brought about significant down-regulation in gene expression levels of cathepsin K, RANKL and RANKL/OPG ratio versus untreated osteoporotic rats. Additionally, osteoblasts nidation could restore bone histoarchitecture. Conclusion: These findings offer scientific evidence that transplanting osteoblasts in osteoporotic rats regains the homeostasis of the bone remodeling cycle, thus providing a promising treatment strategy for primary osteoporosis.


  • Role of nanoparticles in osteogenic differentiation of bone marrow mesenchymal stem cells

    by Nadia S. Mahmoud, Hanaa H. Ahmed, Mohamed R. Mohamed, Khalda S. Amr, Hadeer A. Aglan, Mohamed A. M. Ali, Mohamed A. Tantawy

    The present study aimed to investigate the osteoinductive potentiality of some selected nanostructures; Hydroxyapatite (HA-NPs), Gold (Au-NPs), Chitosan (C-NPs), Gold/hydroxyapatite (Au/HA-NPs) and Chitosan/hydroxyapatite (CH-NPs) on bone marrow- derived mesenchymal stem cells (BM-MSCs). These nanostructures were characterized using transmission electron microscope and Zetasizer. MSCs were isolated from bone marrow of rat femur bones and their identity was documented by morphology, flow cytometry and multi-potency capacity. The influence of the selected nanostructures on the viability, osteogenic differentiation and subsequent matrix mineralization of BM-MSCs was determined by MTT assay, molecular genetic analysis and alizarin red S staining, respectively. MTT analysis revealed insignificant toxicity of the tested nanostructures on BM-MSCs at concentrations ranged from 2 to 25 µg/ml over 48 h and 72 h incubation period. Notably, the tested nanostructures potentiate the osteogenic differentiation of BM-MSCs as evidenced by a prominent over-expression of runt-related transcription factor 2 (Runx-2) and bone morphogenetic protein 2 (BMP-2) genes after 7 days incubation. Moreover, the tested nanostructures induced matrix mineralization of BM-MSCs after 21 days as manifested by the formation of calcium nodules stained with alizarin red S. Conclusively, these data provide a compelling evidence for the functionality of the studied nanostructures as osteoinductive materials motivating the differentiation of BM-MSCs into osteoblasts with the most prominent effect observed with Au-NPs and Au/HA-NPs, followed by CH-NPs.


  • Nanotechnological Applications Hold a Pivotal Position in Boosting Stem Cells Osteogenic Activity: In Vitro and In Vivo Studies

    by Hadeer A. Aglan, Hanaa H. Ahmed, Nadia S. Mahmoud, Riham M. Aly, Naglaa A. Ali, Ahmed A. Abd-Rabou

    This approach was constructed to appraise the therapeutic effectiveness of a single i.v. dose of osteoblasts generated from co-culturing BM-MSCs with nano-HA, Pt-NPs, or Pt-HA-nanocomposite in osteoporotic rats. MSCs were grown, propagated in culture, and characterized. The effect of the suggested nanoplatforms on the survival, osteogenic differentiation, and mineralization of BM-MSCs was assessed by MTT assay, real-time PCR analysis, and Alizarin red S staining, respectively. Thereafter, the generated osteoblasts were employed for the treatment of ovariectomized rats. Our results revealed that the selected nanoplatforms upregulate the expression of osteogenic differentiation related genes (Runx-2 and BMP-2) significantly and enhance calcium deposition in BM-MSCs after 7 and 21 days, respectively, whereas the in vivo study validated that the infusion of the generated osteoblasts considerably downturn serum BALP, BSP, and SOST levels; upswing OSX level; and regain femur bone mineralization and histoarchitecture. Conclusively, the outcomes of this work provide scientific evidence that transplanting osteoblasts derived from differentiation of BM-MSCs in the presence of nanoplatforms in ovariectomized rats restores bone remodeling balance which constitutes a new hope for the treatment of osteoporosis.